Urtasun R C, Chapman J D, Feldstein M L, Band R P, Rabin H R, Wilson A F, Marynowski B, Starreveld E, Shnitka T
Br J Cancer Suppl. 1978 Jun;3:271-5.
The human tolerance to multiple dosages of misonidazole (Ro-07-0582) was studied in 28 patients with different types of malignant neoplasias. The mean total dose for this group of patients was 16.2 g. The main toxicity was peripheral neuropathy with an overall incidence of 35%. This neuropathy occurred more frequently and with greater severity when the drug was administered 3 times a week and when patients received total doses of over 18 g. The best tolerated schedule appears to be once or twice a week up to total dosages of 18 g or less (approximately 11 g/m2). Electron microscopy of a sural nerve biopsy from an affected patient revealed residual of previous distal axonal degeneration, with some segmental demyelination and remyelination, which affected both large and small myelinated nerve fibres.
对28例不同类型恶性肿瘤患者进行了多次剂量米索硝唑（Ro-07-0582）的人体耐受性研究。该组患者的平均总剂量为16.2克。主要毒性为周围神经病变，总发生率为35%。当每周给药3次且患者接受的总剂量超过18克时，这种神经病变发生得更频繁且更严重。耐受性最佳的给药方案似乎是每周一次或两次，总剂量达18克或更少（约11克/平方米）。对一名受影响患者的腓肠神经活检进行电子显微镜检查显示，有先前远端轴突变性的残留，伴有一些节段性脱髓鞘和再髓鞘化，这影响了大小有髓神经纤维。
